BeiGene

From WikiMD's WELLNESSPEDIA

File:BeiGene logo (2021).png
BeiGene logo (2021)

Chinese biotechnology company

BeiGene, Ltd.





TypePublic
Traded asNASDAQ: BGNE , Template:HKEX
Key peopleJohn V. Oyler (CEO)
IndustryBiotechnology
ProductsCancer treatments



BeiGene, Ltd. is a global, commercial-stage biotechnology company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company was founded in 2010 by John V. Oyler and Xiaodong Wang and is headquartered in Beijing, China.

History[edit]

BeiGene was established in 2010 with the aim of creating a world-class biotechnology company in China. The company has since expanded its operations globally, with offices and facilities in the United States, Australia, and various other countries.

Research and Development[edit]

BeiGene's research and development efforts are primarily focused on oncology. The company has a broad pipeline of drug candidates, including both small molecules and biologics. Key areas of research include immuno-oncology, molecularly targeted therapy, and combination therapy.

Products[edit]

BeiGene has developed several drug candidates that are in various stages of clinical development. Some of the notable products include:

Collaborations and Partnerships[edit]

BeiGene has entered into several strategic collaborations and partnerships with leading pharmaceutical companies to advance its drug development programs. These partnerships include collaborations with companies such as Celgene, Amgen, and Novartis.

Stock Market[edit]

BeiGene is publicly traded on the NASDAQ under the ticker symbol BGNE and on the Hong Kong Stock Exchange under the ticker symbol 6160.

See also[edit]

Related pages[edit]

Stub icon

This biotechnology article is a stub. You can help WikiMD by expanding the page.

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=BeiGene&oldid=5896900"